Shopping Cart 0
Cart Subtotal
USD 0

Neuropathic Pain-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Neuropathic Pain-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain-Pipeline Review, H2 2017, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 24, 29, 1, 114, 27 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Neuropathic Pain-Overview

Neuropathic Pain-Therapeutics Development

Neuropathic Pain-Therapeutics Assessment

Neuropathic Pain-Companies Involved in Therapeutics Development

Neuropathic Pain-Drug Profiles

Neuropathic Pain-Dormant Projects

Neuropathic Pain-Discontinued Products

Neuropathic Pain-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Neuropathic Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Neuropathic Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Products under Development by Companies, H2 2017 (Contd..11), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Neuropathic Pain-Pipeline by 2-BBB Medicines BV, H2 2017

Neuropathic Pain-Pipeline by AbbVie Inc, H2 2017

Neuropathic Pain-Pipeline by Abide Therapeutics Inc, H2 2017

Neuropathic Pain-Pipeline by Acadia Pharmaceuticals Inc, H2 2017

Neuropathic Pain-Pipeline by Achelios Therapeutics Inc, H2 2017

Neuropathic Pain-Pipeline by Affectis Pharmaceuticals AG, H2 2017

Neuropathic Pain-Pipeline by AnaBios Corp, H2 2017

Neuropathic Pain-Pipeline by Anavex Life Sciences Corp, H2 2017

Neuropathic Pain-Pipeline by AngioChem Inc, H2 2017

Neuropathic Pain-Pipeline by Aptinyx Inc, H2 2017

Neuropathic Pain-Pipeline by Arena Pharmaceuticals Inc, H2 2017

Neuropathic Pain-Pipeline by Astellas Pharma Inc, H2 2017

Neuropathic Pain-Pipeline by AstraZeneca Plc, H2 2017

Neuropathic Pain-Pipeline by Aucta Pharmaceuticals LLC, H2 2017

Neuropathic Pain-Pipeline by BCI Pharma, H2 2017

Neuropathic Pain-Pipeline by BCN Peptides SA, H2 2017

Neuropathic Pain-Pipeline by Biogen Inc, H2 2017

Neuropathic Pain-Pipeline by Bionomics Ltd, H2 2017

Neuropathic Pain-Pipeline by Bristol-Myers Squibb Co, H2 2017

Neuropathic Pain-Pipeline by Can-Fite BioPharma Ltd, H2 2017

Neuropathic Pain-Pipeline by Cara Therapeutics Inc, H2 2017

Neuropathic Pain-Pipeline by Celgene Corp, H2 2017

Neuropathic Pain-Pipeline by Centrexion Therapeutics Corp, H2 2017

Neuropathic Pain-Pipeline by Cerecor Inc, H2 2017

Neuropathic Pain-Pipeline by Chromocell Corp, H2 2017

Neuropathic Pain-Pipeline by Circuit Therapeutics Inc, H2 2017

Neuropathic Pain-Pipeline by Colby Pharmaceutical Co, H2 2017

Neuropathic Pain-Pipeline by ConSynance Therapeutics Inc, H2 2017

Neuropathic Pain-Pipeline by ContraVir Pharmaceuticals Inc, H2 2017

Neuropathic Pain-Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Neuropathic Pain-Pipeline by Cytogel Pharma LLC, H2 2017

Neuropathic Pain-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Neuropathic Pain-Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Neuropathic Pain-Pipeline by Develco Pharma Schweiz AG, H2 2017

Neuropathic Pain-Pipeline by Dompe Farmaceutici SpA, H2 2017

Neuropathic Pain-Pipeline by Eisai Co Ltd, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

2-BBB Medicines BV

AbbVie Inc

Abide Therapeutics Inc

Acadia Pharmaceuticals Inc

Achelios Therapeutics Inc

Affectis Pharmaceuticals AG

AnaBios Corp

Anavex Life Sciences Corp

AngioChem Inc

Aptinyx Inc

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Aucta Pharmaceuticals LLC

BCI Pharma

BCN Peptides SA

Biogen Inc

Bionomics Ltd

Bristol-Myers Squibb Co

Can-Fite BioPharma Ltd

Cara Therapeutics Inc

Celgene Corp

Centrexion Therapeutics Corp

Cerecor Inc

Chromocell Corp

Circuit Therapeutics Inc

Colby Pharmaceutical Co

ConSynance Therapeutics Inc

ContraVir Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Cytogel Pharma LLC

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Develco Pharma Schweiz AG

Dompe Farmaceutici SpA

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Evec Inc

Genecode AS

GL Pharm Tech Corp

Glialogix Inc

Grunenthal GmbH

GT Biopharma Inc

GW Pharmaceuticals Plc

Hydra Biosciences Inc

Immune Pharmaceuticals Inc

India Globalization Capital Inc

Intec Pharma Ltd

Integral Molecular Inc

IntelGenx Corp

Intellipharmaceutics International Inc

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

JT Pharmaceuticals Inc

Knopp Biosciences LLC

Kolon Life Science Inc

KPI Therapeutics Inc

Lexicon Pharmaceuticals Inc

Lohocla Research Corp

Mapi Pharma Ltd

MD Biosciences GmbH

Medifron DBT Co Ltd

MEDRx Co Ltd

Medy-Tox Inc

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Mundipharma International Ltd

Nanomerics Ltd

Neurim Pharmaceuticals Ltd

Neurocentrx Pharma Ltd

NeuroCycle Therapeutics GmbH

NeurOp Inc

Newron Pharmaceuticals SpA

Nippon Chemiphar Co Ltd

Nippon Zoki Pharmaceutical Co Ltd

NoNO Inc

Novartis AG

Novassay SA

Orexigen Therapeutics Inc

Orion Corporation

Patagonia Pharmaceuticals LLC

PeriphaGen Inc

Pfizer Inc

Pharmaleads SA

Phosphagenics Ltd

RaQualia Pharma Inc

Re-Pharm Ltd

Relmada Therapeutics Inc

Revance Therapeutics Inc

Rottapharm Biotech Srl

Saniona AB

Scilex Pharmaceuticals Inc

Shionogi & Co Ltd

Sunovion Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Teva Pharmaceutical Industries Ltd

Theranexus SAS

Toray Industries Inc

Torrent Pharmaceuticals Ltd

Trevena Inc

Vertex Pharmaceuticals Inc

Virobay Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Yooyoung Pharm Co Ltd

Yuhan Corp

Yungjin Pharm Co Ltd

Zynerba Pharmaceuticals Inc